Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cheaper stents vs. pricier ones: which is better value for liver patients?

NCT ID NCT00593528

Disease control Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at two types of stents used in a procedure called TIPS, which creates a bypass in the liver to relieve complications of cirrhosis. One stent is covered with a special material to stay open longer but costs more; the other is a standard bare stent that is cheaper but may need more follow-up procedures. Researchers compared how well each stent worked and their overall cost-effectiveness in 138 patients with liver cirrhosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

138 people

The number who actually took part.

Started

Feb 2008

Finished

Jul 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Presence of a cirrhosis as documented by previous liverbiopsy or typical clinical signs * Indication validated of the TIPS (Bavéno IV), except not-controlled acute hemorrhagic : * Recurrent variceal bleeding after failure of the usual pharmacological and endoscopic methods * Refractory or recurrent ascites or difficult to treat * Refractory Hydrothorax Exclusion Criteria: * Non cirrhotic HTP * CHILD C ≥12 * Complete portal vein thrombosis * Usual contra-indication for TIPS : * Known or suspected Hepatocarcinoma by increase of the alpha-foetoprotein \>100 UI/mL associated with the presence of at least one hepatic nodule * Cardiac insufficiency defined by a ventricular fraction of ejection \< 40% with the echocardiography preliminary to the procedure * Pulmonary arterial hypertension (PAP \> 40 mmHg) * Hepatic polycystosis * Intra-hepatic bile ducts dilatation, * Spontaneous clinical recurrent hepatic encephalopathy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhotic portal hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fibrosis portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cirrhotic portal hypertension

Contacts and locations

Locations

  • AP-HM / La Conception

    Marseille, 13003, France

  • AP-HM / La Timone

    Marseille, 13385, France

  • Ap-Hp (Paul Brousse)

    Villejuif, 94804, France

  • CHRU NANTES / Hôpital Guillaume et René Laënnec

    Nantes, 44800, France

  • CHRU NANTES / Hôtel-Dieu

    Nantes, 44093, France

  • CHRU de TOURS

    Tours, 37044, France

  • Chru Bordeaux

    Bordeaux, 33075, France

  • Chru Caen

    Caen, 14033, France

  • Chru Clermont Ferrand

    Clermont-Ferrand, 63058, France

  • Chru Dijon

    Dijon, 21079, France

  • Chru Nice

    Nice, 06202, France

  • Chru Poitiers

    Poitiers, 86021, France